2011年 IAAO

国際フォーラム2011(IAAO2011)

Theme:Strategy for Clinical Trial in Personalized Medicine

Greeting

201101 Osamu Nagayama, Chairman
Chugai Academy for Advanced Oncology

Opening Remarks

201102 Bruce Chabner, MD
Director of Clinical Research, Cancer Center
Massachusetts General Hospital, Boston Massachusetts

▶ Symposium 1 Personalized medicine; Targeting ALK-fusion

201103
Chair:
Hiroyuki Mano, MD, PhD
Jichi Medical University/Graduate School of Medicine, The University of Tokyo, Japan
Nagahiro Saijo, MD, PhD
Kinki University, School of Medicine, Japan

▶ S1-1. Discovery of EML4-ALK fusion oncogene

201104
Speaker:
Hiroyuki Mano, MD, PhD
Professor of Medicine, Department of Medical Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo
Professor of Medicine, Division of Functional Genomics, Jichi Medical University, Tochigi

▶ S1-2. Exploring for ALKoma with use of integrated diagnostic techniques

201105
Speaker:
Kengo Takeuchi, MD, PhD
Project leader / Senior staff scientist, Pathology Project for Molecular Targets /Division of Pathology, The Cancer Institute Japanese Foundation for Cancer Research

▶ S1-3. Clinical trials with ALK inhibitor

201106
Speaker:
Pasi Antero Jänne, MD, PhD
Associate Professor of Medicine, Dana-Farber Cancer Institute, USA

▶ S1-4. A large scale screening of ALK fusions

201107
Speaker:
A. John Iafrate, MD, PhD
Associate Pathologist, Massachusetts General Hospital
Associate Professor of Pathology, Department of Pathology, Harvard Medical School, USA

▶ Symposium 2 Synthetic lethality; Theory and Practice

201108
Chair:
Kiyohiko Hatake, MD, PhD
Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
Yuko Kitagawa, MD, PhD
Keio University School of Medicine, Japan

▶ S2-1. Some practical issues related to shRNA/siRNA screens in mammalian cells(cancelled)

Speaker:
William Kaelin, MD
Professor of Medicine, Harvard Medical School
Division of Medical Oncology/Molecular and Cellular, Dana-Farber Cancer Institute, USA

▶ S2-2. Application of synthetic lethality to cancer therapy

201109
Speaker:
Christopher Lord, PhD
Senior Staff Scientist, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, UK

▶ Special Lecture

“The Methodological Challenge of delivering personalised therapy for cancer patients”

201110201111
Chair:
Kiyohiko Hatake, MD, PhD
Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
Nobuyuki Mizunuma,MD
Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan

 

Speaker:
Patrick G. Johnston, MD, PhD
Dean, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University BelfastDirector, Institute of Health & Life Sciences, Queen’s University Belfast, UK

 

▶ Symposium3 Therapeutic Inhibition of oncogenic signaling

201112
Chair:
Masakazu Toi, MD, PhD
Kyoto University School of Medicine, Japan
Chikashi Ishioka, MD
Tohoku University School of Medicine, Japan

▶ S3-1. PI3K pathway: Therapeutic targeting of malignancy

201113 Speaker:
Jose Baselga, MD, PhD
Professor, Department of Medicine, Harvard Medical School
Associate Director, MGH Cancer Center, Medicine, Massachusetts General Hospital
Chief, Hematology/Oncology, Medicine, Massachusetts General Hospital, USA

 

▶ S3-2. Genetic predictors of RAF-dependence.

201114
Speaker:
David B. Solit, MD
Elizabeth and Felix Rohatyn Chair for Junior Faculty, Memorial Sloan-Kettering Cancer Center, USA

▶ S3-3. Feedback and redundancy of oncogenic signaling pathways

201115
Speaker:
Neal Rosen, MD, PhD
Enid A. Haupt Chair in Medical Oncology
Member, Department of Medicine
Member, Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, NY
Professor of Pharmacology, Cornell University Graduate School of Medical Sciences, New York, NY
Professor of Medicine, Joan and Sanford I. Weill Medical College, Cornell University, New York, NY, USA

Closing

201116 Makoto Ogawa, MD
Emeritus President, Aichi Cancer Center, Japan
一般社団法人 中外Oncology学術振興会議